Cookson Peirce & Co. Inc. Reduces Position in Boston Scientific Corporation $BSX

Key Points

• Cookson Peirce & Co. Inc. reduced its Boston Scientific stake by 47.5% in the fourth quarter, though it still held 141,817 shares worth about $13.5 million.
• Institutional interest in BSX remains strong overall, with several large hedge funds adding positions and 89.07% of the stock now owned by institutions.
• Analysts remain mostly positive despite trimming price targets: Boston Scientific has a consensus “Moderate Buy” rating, and the company also recently authorized a $5 billion stock buyback and reported earnings and revenue that slightly beat expectations.

Cookson Peirce & Co. Inc. cut its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 47.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 141,817 shares of the medical equipment provider's stock after selling 128,160 shares during the period. Cookson Peirce & Co. Inc.'s holdings in Boston Scientific were worth $13,522,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in BSX. Norges Bank bought a new position in shares of Boston Scientific in the fourth quarter worth about $2,199,395,000. Egerton Capital UK LLP grew its holdings in shares of Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd bought a new position in shares of Boston Scientific in the fourth quarter worth about $252,918,000. Marshall Wace LLP grew its holdings in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider's stock worth $956,680,000 after purchasing an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A bought a new position in shares of Boston Scientific in the third quarter worth about $204,812,000. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BSX. Citigroup cut their price target on shares of Boston Scientific from $87.00 to $70.00 and set a "buy" rating on the stock in a report on Thursday, May 28th. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a report on Wednesday, May 27th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, May 28th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Jefferies Financial Group cut their price target on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $85.92.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Activity

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of the company's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Cheryl Pegus acquired 1,770 shares of the company's stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company's stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Price Performance

NYSE BSX opened at $48.66 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm's 50 day moving average price is $58.11 and its 200-day moving average price is $76.70. Boston Scientific Corporation has a 52-week low of $47.17 and a 52-week high of $109.50. The company has a market cap of $72.32 billion, a PE ratio of 20.36, a P/E/G ratio of 0.91 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm earned $0.75 earnings per share. The company's quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.